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OBJECTIVE: To evaluate the natural history of MEN1-related bronchial endocrine
tumors (br-NETs) and to determine their histological characteristics, survival and
causes of death. br-NETs frequency ranges from 3 to 13% and may reach 32%
depending on the number of patients evaluated and on the criteria required for
diagnosis.
METHODS: The 1023-patient series of symptomatic MEN1 patients followed up in a
median of 48.7 [35.5-59.6] years by the Groupe d'étude des Tumeurs Endocrines was
analyzed using time-to-event techniques.
RESULTS: br-NETs were found in 51 patients (4.8%, [95% CI 3.6-6.2%]) and were
discovered by imaging in 86% of cases (CT scan, Octreoscan, Chest X-ray, MRI).
Median age at diagnosis was 45 years [28-66]. Histological examination showed 27
(53%) typical carcinoids (TC), 16 (31%) atypical carcinoids (AC), 2 (4%) large cell
neuroendocrine carcinomas (LCNEC), 3(6%) small cell neuroendocrine carcinomas
(SCLC), 3(6%) TC associated with AC. Overall survival was not different from the rest
of the cohort (HR 0.29, [95% CI 0.02-5.14]). AC tended to have a worse prognosis
than TC (p = 0.08). Seven deaths were directly related to br-NETs (three AC, three
SCLC and one LCNEC). Patients who underwent surgery survived longer (p = 10)
and were metastasis free, while 8 of 14 non-operated patients were metastatic. There
were no operative deaths.
CONCLUSIONS: Around 5% of MEN1 patients develop br-NETs. br-NETs do not
decrease overall survival in MEN1 patients, but poorly differentiated and aggressive
br-NETs can cause death. br-NETs must be screened carefully. A biopsy is essential
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